Neurocognitive Effects of Chemotherapy for Colorectal Cancer: A Systematic Review and a Meta-Analysis of 11 Studies

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2021 Mar 18

PMID 33735557

Citations 4

Authors

Soo Young Hwang

Kwanghyun Kim

Byeonggwan Ha

Dongkyu Lee

Seonung Kim

Seongjun Ryu

Jisu Yang

Sun Jae Jung

Affiliations

Soon will be listed here.

Abstract

Purpose: Chemotherapy-related cognitive impairment (CRCI) is a controversial concept not much explored on colorectal cancer patients.

Materials And Methods: We identified 11 prospective studies: eight studies on 696 colorectal cancer patients who received chemotherapy and three studies on 346 rectal cancer patients who received neoadjuvant chemoradiotherapy. Standardized mean differences (SMDs) of neuropsychological test results and the cognitive quality-of-life scale were calculated using random effect models. A meta-regression was conducted to investigate the association between mean study population age and effect sizes.

Results: The association between chemotherapy and cognitive impairment was not clear in colorectal cancer patients (SMD, 0.003; 95% confidence interval, ‒0.080 to 0.086). However, a meta-regression showed that older patients are more vulnerable to CRCI than younger patients (β=‒0.016, p < 0.001).

Conclusion: Chemotherapy has an overall positive negligible effect size on the cognitive function of colorectal patients. Age is a significant moderator of CRCI.

Citing Articles

Changes in chemotherapy-induced cognitive impairment in gastrointestinal cancer survivors using multidomain assessments: a prospective cohort study.

Saita K, Tanabe K, Hamai Y, Yamauchi M, Kaneko F, Mikami Y J Cancer Surviv. 2025; .

PMID: 39954221 DOI: 10.1007/s11764-025-01759-8.

Neurological Complications of Conventional and Novel Anticancer Treatments.

Alberti P, Salvalaggio A, Argyriou A, Bruna J, Visentin A, Cavaletti G Cancers (Basel). 2022; 14(24).

PMID: 36551575 PMC: 9776739. DOI: 10.3390/cancers14246088.

Chemotherapy-induced functional brain abnormality in colorectal cancer patients: a resting-state functional magnetic resonance imaging study.

Liu S, Guo Y, Ni J, Yin N, Li C, Pan X Front Oncol. 2022; 12:900855.

PMID: 35924154 PMC: 9339615. DOI: 10.3389/fonc.2022.900855.

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy.

Salzmann M, Hess K, Lang K, Enk A, Jordan B, Hassel J Strahlenther Onkol. 2022; 198(10):884-891.

PMID: 35546362 PMC: 9515012. DOI: 10.1007/s00066-022-01950-1.

Effect of chemotherapy and radiotherapy on cognitive impairment in colorectal cancer: evidence from Korean National Health Insurance Database Cohort.

Kim K, Kim C, Shin A, Kang H, Jung S Epidemiol Health. 2021; 43:e2021093.

PMID: 34735757 PMC: 8920736. DOI: 10.4178/epih.e2021093.

References

Branca J, Maresca M, Morucci G, Becatti M, Paternostro F, Gulisano M . Oxaliplatin-induced blood brain barrier loosening: a new point of view on chemotherapy-induced neurotoxicity. Oncotarget. 2018; 9(34):23426-23438. PMC: 5955120. DOI: 10.18632/oncotarget.25193. View

Horowitz T, Trevino M, Gooch I, Duffy K . Understanding the Profile of Cancer-Related Cognitive Impairments: A Critique of Meta-Analyses. J Natl Cancer Inst. 2019; 111(10):1009-1015. PMC: 6792125. DOI: 10.1093/jnci/djz100. View

Andreis F, Ferri M, Mazzocchi M, Meriggi F, Rizzi A, Rota L . Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study. Support Care Cancer. 2012; 21(2):583-90. DOI: 10.1007/s00520-012-1560-2. View

van Dam F, Schagen S, Muller M, Boogerd W, vd Wall E, Droogleever Fortuyn M . Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90(3):210-8. DOI: 10.1093/jnci/90.3.210. View

Pendergrass J, Targum S, Harrison J . Cognitive Impairment Associated with Cancer: A Brief Review. Innov Clin Neurosci. 2018; 15(1-2):36-44. PMC: 5819720. View

Wigmore P, Mustafa S, El-Beltagy M, Lyons L, Umka J, Bennett G . Effects of 5-FU. Adv Exp Med Biol. 2010; 678:157-64. DOI: 10.1007/978-1-4419-6306-2_20. View

Anderson-Hanley C, Sherman M, Riggs R, Agocha V, Compas B . Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2004; 9(7):967-82. DOI: 10.1017/S1355617703970019. View

Bleecker M, Ford D, Celio M, Vaughan C, Lindgren K . Impact of cognitive reserve on the relationship of lead exposure and neurobehavioral performance. Neurology. 2007; 69(5):470-6. DOI: 10.1212/01.wnl.0000266628.43760.8c. View

Anampa J, Makower D, Sparano J . Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015; 13:195. PMC: 4538915. DOI: 10.1186/s12916-015-0439-8. View

10.

Wefel J, Vardy J, Ahles T, Schagen S . International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011; 12(7):703-8. DOI: 10.1016/S1470-2045(10)70294-1. View

11.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

12.

Vardy J, Dhillon H, Pond G, Rourke S, Bekele T, Renton C . Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. J Clin Oncol. 2015; 33(34):4085-92. PMC: 5683012. DOI: 10.1200/JCO.2015.63.0905. View

13.

Bernstein L, McCreath G, Komeylian Z, Rich J . Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: A multilevel meta-analysis. Neurosci Biobehav Rev. 2017; 83:417-428. DOI: 10.1016/j.neubiorev.2017.10.028. View

14.

Bianchi E, Di Cesare Mannelli L, Micheli L, Farzad M, Agliano M, Ghelardini C . Apoptotic Process Induced by Oxaliplatin in Rat Hippocampus Causes Memory Impairment. Basic Clin Pharmacol Toxicol. 2016; 120(1):14-21. DOI: 10.1111/bcpt.12629. View

15.

Fardell J, Vardy J, Shah J, Johnston I . Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl). 2011; 220(1):183-93. DOI: 10.1007/s00213-011-2466-2. View

16.

Maccormick R . Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty?. Med Hypotheses. 2006; 67(2):212-5. DOI: 10.1016/j.mehy.2006.01.045. View

17.

Souza J, Nahas C, Nahas S, Sparapan Marques C, Ribeiro Junior U, Cecconello I . HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PATIENTS WITH RECTAL CANCER TREATED WITH CURATIVE INTENT. Arq Gastroenterol. 2018; 55(2):154-159. DOI: 10.1590/S0004-2803.201800000-27. View

18.

Ahles T, Saykin A . Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007; 7(3):192-201. PMC: 3329763. DOI: 10.1038/nrc2073. View

19.

Fernandes H, Richard N, Edelstein K . Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review. Support Care Cancer. 2019; 27(9):3253-3279. DOI: 10.1007/s00520-019-04866-2. View

20.

Falleti M, Sanfilippo A, Maruff P, Weih L, Phillips K . The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005; 59(1):60-70. DOI: 10.1016/j.bandc.2005.05.001. View